ALAWAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALAWAY (ALAWAY).
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
| Metabolism | Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption. |
| Excretion | Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination. |
| Half-life | Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency. |
| Protein binding | Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa. |
| Bioavailability | Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%. |
| Onset of Action | Oral: ~30 minutes (time to detectable serum levels); peak effect 1-2 hours. Topical (ophthalmic): within 15-30 minutes for ocular symptoms. Intravenous: immediate (minutes). |
| Duration of Action | Oral: 8-12 hours (symptom relief). Topical: 6-8 hours. Clinical note: Duration may be shorter in patients with rapid metabolism or severe allergic reactions. |
| Molecular Weight | 256.34 |
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin. |
| Liver impairment | No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established. |
| Pediatric use | Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established. |
| Geriatric use | No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal. |
| 1st trimester | Category C: Fetal risk cannot be ruled out. Consider risks vs benefits. |
| 2nd trimester | Category C: Use only if potential benefit justifies potential risk. |
| 3rd trimester | Category C: Avoid near term due to potential adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for ALAWAY (ALAWAY).
| Placental transfer | Crosses placenta; minimal data available. |
| Breastfeeding | Excreted into breast milk in low concentrations; use with caution in nursing mothers. |
| Lactation Rating | L3 - Moderately Safe |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to drug or classSevere renal impairment
| Precautions | For topical ophthalmic use only, Do not inject, Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting, May cause temporary blurred vision, Avoid touching dropper tip to any surface to prevent contamination |
| Food/Dietary | No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence. |
| Fetal Monitoring | Monitor for maternal adverse effects: somnolence, dizziness, bitter taste (dysgeusia). No specific fetal monitoring indicated. In third trimester, assess fetal heart rate and growth if maternal use is prolonged or high-dose. No routine laboratory monitoring required. |
| Fertility Effects | In animal studies, oral azelastine did not impair fertility in rats at doses up to 30 mg/kg/day (210 times the maximum recommended human intranasal dose). No human data on fertility effects. Based on mechanism and pharmacokinetics, clinically significant impact on human fertility is unlikely at recommended intranasal doses. |
| Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting. |
| Patient Advice | Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting. · Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses. · Do not use while wearing contact lenses if eyes are red or irritated. · Temporary burning or stinging may occur upon instillation. |